Early Statin Therapy in Acute Coronary SyndromesThe Successful Cycle of Evidence, Guidelines, and Implementation
David D. Waters, MD* and
Ivy Ku, MD
Division of Cardiology, San Francisco General Hospital, San Francisco, California; and the University of California, San Francisco School of Medicine, San Francisco, California
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 HRs and 95% CIs at Various Time Points Throughout the PROVE-IT Trial
The primary end point is a composite of death, myocardial infarction, unstable angina requiring hospitalization, urgent revascularization after 30 days, or stroke. The triple composite end point is death, myocardial infarction, or rehospitalization with acute coronary syndrome. The benefit of atorvastatin 80 mg compared with pravastatin 40 mg is already statistically significant for the triple composite end point by 30 days and remains so during the entire follow-up. Adapted, with permission, from Ray et al. (16). CI = confidence interval; HR = hazard ratio.
|
|
|
